<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3099">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01434680</url>
  </required_header>
  <id_info>
    <org_study_id>V14_57</org_study_id>
    <nct_id>NCT01434680</nct_id>
  </id_info>
  <brief_title>Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy Toddlers</brief_title>
  <official_title>A Phase 2, Randomized, Comparative, Multicenter Observer-Blind Study Evaluating the Safety and Immunogenicity of the New Liquid Formulation of Novartis Meningococcal C Conjugate Vaccine and of the Novartis Lyophilized Meningococcal C Conjugate Vaccine Manufactured at Two Different Sites, in Healthy Toddlers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>Poland: The Central Register of Clinical Trials</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study was to evaluate the safety and and immune response of each of three lots of
      Novartis Meningococcal C Conjugate Vaccine (MenC-CRM Liquid) when administered to Healthy
      Toddlers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Geometric Mean Human Serum Bactericidal Activity Titers Against N Meningitidis Serogroup C 28 Days After Vaccination</measure>
    <time_frame>1 month postvaccination (day 29)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Immunogenicity was measured by human serum bactericidal activity (hSBA) geometric mean titers (GMTs)against N meningitidis type C, at day 29 after a single vaccination when administered to toddlers to assess the equivalence of MenC-CRM LIQ to MenC-CRM EMV and MenC-CRM ROS to MenC-CRM EMV.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean hSBA Titers Against N Meningitidis Serogroup C 28 Days After Vaccination</measure>
    <time_frame>1 month postvaccination (day 29)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Immunogenicity was measured by hSBA GMTs against N meningitidis type C, approximately 28 days (at day 29) after a single vaccination when administered to toddlers to assess the equivalence of MenC-CRM LIQ to MenC-CRM ROS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number Of Subjects Reporting Solicited Local And Systemic Adverse Events</measure>
    <time_frame>From day 1 through day 7</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety was assessed as the number of subjects who reported solicited local and systemic adverse events following a single injection with either MenC-CRM LIQ or MenC-CRM ROS or MenC-CRM EMV.
Safety was also assessed in subjects who mistakenly received MenC-CRM EMV instead of MenC-CRM ROS.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">992</enrollment>
  <condition>Meningococcal Disease</condition>
  <condition>Meningococcal Meningitis</condition>
  <arm_group>
    <arm_group_label>MenC-CRM LIQ (Liquid Formulation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 1 injection of MenC-CRM vaccine,liquid formulation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MenC-CRM ROS (Rosia)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 1 injection of MenC-CRM vaccine, lyophilized formulation produced with drug substance manufactured at Rosia, Italy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MenC-CRM EMV (Emeryville)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received 1 injection of MenC-CRM vaccine, lyophilized formulation produced with drug substance manufactured at Emeryville, USA</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MenC-CRM LIQ</intervention_name>
    <description>One dose of MenC-CRM vaccine, liquid formulation</description>
    <arm_group_label>MenC-CRM LIQ (Liquid Formulation)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MenC-CRM ROS</intervention_name>
    <description>One dose of MenC-CRM vaccine, lyophilized formulation produced with drug substance manufactured at Rosia, Italy.</description>
    <arm_group_label>MenC-CRM ROS (Rosia)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MenC-CRM EMV</intervention_name>
    <description>One dose of MenC-CRM vaccine, lyophilized formulation produced with drug substance manufactured at Emeryville, USA.</description>
    <arm_group_label>MenC-CRM EMV (Emeryville)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy 12 - 23 (inclusive) month-old male or female toddlers.

          2. A parent/legal guardian was given written informed consent after the nature of the
             study has been explained.

          3. Available for both the visits scheduled in the study.

          4. In good health as determined by medical history, physical examination and clinical
             judgment of the investigator.

        Exclusion Criteria:

          1. History of any meningococcal vaccine administration.

          2. Previous known or suspected disease caused by N. meningitidis.

          3. Household contact with and/or intimate exposure to an individual with laboratory
             confirmed N. meningitidis infection or colonization.

          4. History of severe allergic reaction after previous vaccinations, allergy to Latex, or
             hypersensitivity to any component of the vaccine.

          5. Significant acute or chronic infection within the previous 7 days or axillary
             temperature ≥38.0°C within the previous 3 days.

          6. Individuals who have received antibiotics within 6 days before vaccination.

          7. Known or suspected autoimmune disease or impairment/alteration of the immune system
             resulting from (for example):

               -  Receipt of any immunosuppressive therapy at any time since birth.

               -  Receipt of any immunostimulants at any time since birth.

               -  Receipt of any systemic corticosteroids or chronic use of inhaled high-potency
                  corticosteroids since birth (use of topical corticosteroids administered in
                  limited areas of the body [for example, eczema on knees or face or elbows] is
                  allowed).

               -  Immune deficiency disorder, or known HIV infection.

          8. History of seizure, any progressive neurological disease or Guillain Barré Syndrome
             (exception: one self-limited non-medicated febrile seizure is acceptable).

          9. Known bleeding diathesis, or any condition that may be associated with a prolonged
             bleeding time.

         10. Receipt of blood, blood products and/or plasma derivatives or any parenteral
             immunoglobulin preparation in the past 12 weeks.

         11. Taken any antipyretic medication in the previous 6 hours.

         12. Received any other vaccines within 30 days prior to enrollment or intent to receive
             any other vaccine during the study (Exception: Inactivated influenza vaccine may be
             administered up to 15 days prior to study immunization and no less than 15 days after
             study immunization).

         13. Toddler's parent(s) or legal guardian(s) are not able to comprehend and to follow all
             required study procedures for the whole period of the study.

         14. Participation in any clinical trial with another investigational product 30 days
             prior to first study visit or intent to participate in another clinical study during
             this study.

         15. Family members or household members of site research staff.

         16. History or any illness/condition that, in the opinion of the investigator, might
             interfere with the results of the study or pose additional risk to the subjects due
             to participation in the study.

         17. Any serious chronic or progressive disease according to judgment of the investigator
             (neoplasm, insulin dependent diabetes, cardiac, renal or hepatic disease).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>23 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NZOZ Bioscience Sp zoo</name>
      <address>
        <city>ul Czerkaska</city>
        <state>Bydgoszcz</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department Infection Disease ZOZ</name>
      <address>
        <city>Dept Infection Disease ZOZ</city>
        <state>Debica</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Graniczna Sp zoo</name>
      <address>
        <city>ul Graniczna 45</city>
        <state>Katowice</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ HIPOKRATES IIspzoo</name>
      <address>
        <city>Ul Strzelecka 2</city>
        <state>Krakow</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Specjalistyczny Szpital im dr Wl Bieganskiego</name>
      <address>
        <city>ul. Kniaziewicza 1-5</city>
        <state>Lodz</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specjalistyczny Zespol</name>
      <address>
        <city>Ul Krysiewicza</city>
        <state>Poznan</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZLA Michalkowice Jarosz i Partnerzy Spolka Lekarska</name>
      <address>
        <city>NZLA Michalkowice Jarosz Partnerzy Spolka Lekarska</city>
        <state>Siemianowice Slaskie</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zespol Przychodni Specjalistycznych SP ZOZ w Tarnowie</name>
      <address>
        <city>E Szczeklik Hospital</city>
        <state>Tarnów</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Zespol Publicznych Zakladow Opieki Zdrowotnej w</name>
      <address>
        <city>Ul Prusicka 5355</city>
        <state>Trzebnica</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Pediatrii Centrum Medycznego Ksztalcenia Podyplomowe</name>
      <address>
        <city>Ceglowska 80</city>
        <state>Warszawa</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amicur_Krystyna Lechka-Florianska i Partnerzy</name>
      <address>
        <city>Ul O Bujwida</city>
        <state>Wroclaw</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 24, 2014</lastchanged_date>
  <firstreceived_date>September 14, 2011</firstreceived_date>
  <firstreceived_results_date>July 18, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Meningococcal disease</keyword>
  <keyword>vaccines</keyword>
  <keyword>toddlers</keyword>
  <keyword>prevention</keyword>
  <keyword>Meningitis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Meningitis</mesh_term>
    <mesh_term>Meningitis, Meningococcal</mesh_term>
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled at eleven sites in Poland.</recruitment_details>
      <pre_assignment_details>All enrolled subjects were included in the trial. Data from the group MenC-CRM ROS_EMV was not included in the primary and secondary analyses as these subjects were initially enrolled in group MenC-CRM ROS, but wrongly vaccinated with MenC-CRM EMV.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>MenC-CRM LIQ</title>
          <description>Subjects received 1 injection of MenC-CRM vaccine, liquid formulation.</description>
        </group>
        <group group_id="P2">
          <title>MenC-CRM ROS</title>
          <description>Subjects received 1 injection of MenC-CRM vaccine, lyophilized formulation produced with drug substance manufactured at Rosia, Italy.</description>
        </group>
        <group group_id="P3">
          <title>MenC-CRM EMV</title>
          <description>Subjects received 1 injection of MenC-CRM vaccine, lyophilized formulation produced with drug substance manufactured at Emeryville, USA.</description>
        </group>
        <group group_id="P4">
          <title>MenC-CRM ROS_EMV</title>
          <description>Subjects enrolled to receive MenC-CRM ROS, but were mistakenly administered 1 injection of MenC-CRM EMV</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="299"/>
                <participants group_id="P2" count="268"/>
                <participants group_id="P3" count="306"/>
                <participants group_id="P4" count="119"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="296"/>
                <participants group_id="P2" count="266"/>
                <participants group_id="P3" count="304"/>
                <participants group_id="P4" count="119"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MenC-CRM LIQ</title>
          <description>Subjects received 1 injection of MenC-CRM vaccine, liquid formulation.</description>
        </group>
        <group group_id="B2">
          <title>MenC-CRM ROS</title>
          <description>Subjects received 1 injection of MenC-CRM vaccine, lyophilized formulation produced with drug substance manufactured at Rosia, Italy.</description>
        </group>
        <group group_id="B3">
          <title>MenC-CRM EMV</title>
          <description>Subjects received 1 injection of MenC-CRM vaccine, lyophilized formulation produced with drug substance manufactured at Emeryville, USA.</description>
        </group>
        <group group_id="B4">
          <title>MenC-CRM ROS_EMV</title>
          <description>Subjects enrolled to receive MenC-CRM ROS, but were mistakenly administered 1 injection of MenC-CRM EMV</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="299"/>
                <measurement group_id="B2" value="268"/>
                <measurement group_id="B3" value="306"/>
                <measurement group_id="B4" value="119"/>
                <measurement group_id="B5" value="992"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="16.4" spread="3.4"/>
                <measurement group_id="B2" value="16.2" spread="3.2"/>
                <measurement group_id="B3" value="16.7" spread="3.4"/>
                <measurement group_id="B4" value="17.2" spread="3.3"/>
                <measurement group_id="B5" value="16.5" spread="3.3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="143"/>
                <measurement group_id="B2" value="131"/>
                <measurement group_id="B3" value="141"/>
                <measurement group_id="B4" value="50"/>
                <measurement group_id="B5" value="465"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="156"/>
                <measurement group_id="B2" value="137"/>
                <measurement group_id="B3" value="165"/>
                <measurement group_id="B4" value="69"/>
                <measurement group_id="B5" value="527"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Human Serum Bactericidal Activity Titers Against N Meningitidis Serogroup C 28 Days After Vaccination</title>
        <description>Immunogenicity was measured by human serum bactericidal activity (hSBA) geometric mean titers (GMTs)against N meningitidis type C, at day 29 after a single vaccination when administered to toddlers to assess the equivalence of MenC-CRM LIQ to MenC-CRM EMV and MenC-CRM ROS to MenC-CRM EMV.</description>
        <time_frame>1 month postvaccination (day 29)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was done on the per protocol (PP) set, i.e. the subjects who received the vaccine correctly; provided evaluable serum samples at the relevant time points; and had no major protocol violations as defined prior to analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>MenC-CRM LIQ</title>
            <description>Subjects received 1 injection of MenC-CRM vaccine, liquid formulation.</description>
          </group>
          <group group_id="O2">
            <title>MenC-CRM ROS</title>
            <description>Subjects received 1 injection of MenC-CRM vaccine, lyophilized formulation produced with drug substance manufactured at Rosia, Italy.</description>
          </group>
          <group group_id="O3">
            <title>MenC-CRM EMV</title>
            <description>Subjects received 1 injection of MenC-CRM vaccine, lyophilized formulation produced with drug substance manufactured at Emeryville, USA.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="283"/>
                  <measurement group_id="O2" value="259"/>
                  <measurement group_id="O3" value="281"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Geometric Mean Human Serum Bactericidal Activity Titers Against N Meningitidis Serogroup C 28 Days After Vaccination</title>
            <description>Immunogenicity was measured by human serum bactericidal activity (hSBA) geometric mean titers (GMTs)against N meningitidis type C, at day 29 after a single vaccination when administered to toddlers to assess the equivalence of MenC-CRM LIQ to MenC-CRM EMV and MenC-CRM ROS to MenC-CRM EMV.</description>
            <units>Titers</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Day 1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.1" lower_limit="2" upper_limit="2.2"/>
                  <measurement group_id="O2" value="2.16" lower_limit="2.05" upper_limit="2.26"/>
                  <measurement group_id="O3" value="2.15" lower_limit="2.05" upper_limit="2.25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 29</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9.84" lower_limit="8.39" upper_limit="12"/>
                  <measurement group_id="O2" value="14" lower_limit="12" upper_limit="16"/>
                  <measurement group_id="O3" value="12" lower_limit="10" upper_limit="14"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The study would be considered a success if the two-sided 95% confidence intervals (CIs) for the hSBA GMT ratios comparing MenC-CRM LIQ to MenC-CRM EMV at 28 days after a single vaccination were both within the equivalence interval (0.5, 2.0).</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The equivalence margin was (0.5, 2.0). If the two-sided 95% CI for the ratio of the hSBA GMTs at 28 days following vaccination was within this equivalence interval for each of the two coprimary comparisons, MenC-CRM LIQ and MenC-CRM EMV would be declared equivalent with respect to the immune response to the vaccines.</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
            <method_desc>95% CIs for the GMTs ratios was obtained by exponentiating difference of least square means of log10 transformed titers and both the limits of 95% CIs</method_desc>
            <param_type>hSBA GMT ratios</param_type>
            <param_value>0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The study would be considered a success if the two-sided 95% confidence intervals (CIs) for the hSBA GMT ratios comparing MenC-CRM ROS to MenC-CRM EMV at 28 days after a single vaccination were both within the equivalence interval (0.5, 2.0).</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The equivalence margin was (0.5, 2.0). If the two-sided 95% CI for the ratio of the hSBA GMTs at 28 days following vaccination was within this equivalence interval for each of the two coprimary comparisons,MenC-CRM ROS and MenC-CRM EMV would be declared equivalent with respect to the immune response to the vaccines.</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
            <method_desc>95% CIs for the GMTs ratios was obtained by exponentiating difference of least square means of log10-transformed titers and both the limits of 95% CIs</method_desc>
            <param_type>hSBA GMT ratios</param_type>
            <param_value>1.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>1.41</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean hSBA Titers Against N Meningitidis Serogroup C 28 Days After Vaccination</title>
        <description>Immunogenicity was measured by hSBA GMTs against N meningitidis type C, approximately 28 days (at day 29) after a single vaccination when administered to toddlers to assess the equivalence of MenC-CRM LIQ to MenC-CRM ROS.</description>
        <time_frame>1 month postvaccination (day 29)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was done on the per protocol (PP) set.</population>
        <group_list>
          <group group_id="O1">
            <title>MenC-CRM LIQ</title>
            <description>Subjects received 1 injection of MenC-CRM vaccine, liquid formulation.</description>
          </group>
          <group group_id="O2">
            <title>MenC-CRM ROS</title>
            <description>Subjects received 1 injection of MenC-CRM vaccine, lyophilized formulation produced with drug substance manufactured at Rosia, Italy.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="283"/>
                  <measurement group_id="O2" value="259"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Geometric Mean hSBA Titers Against N Meningitidis Serogroup C 28 Days After Vaccination</title>
            <description>Immunogenicity was measured by hSBA GMTs against N meningitidis type C, approximately 28 days (at day 29) after a single vaccination when administered to toddlers to assess the equivalence of MenC-CRM LIQ to MenC-CRM ROS.</description>
            <units>Titers</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Day 1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.1" lower_limit="2" upper_limit="2.2"/>
                  <measurement group_id="O2" value="2.16" lower_limit="2.05" upper_limit="2.26"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 29</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9.84" lower_limit="8.39" upper_limit="12"/>
                  <measurement group_id="O2" value="14" lower_limit="12" upper_limit="16"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The secondary objective was to be assessed only if both primary objectives were met. Because of this, no adjustment for multiplicity was required. MenC-CRM liquid would be declared equivalent to MenC-CRM ROS if the two-sided 95% CI for the ratio of the hSBA GMTs at approximately 28 days following vaccination was within the equivalence interval (0.5, 2.0).</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The equivalence margin was (0.5, 2.0). If the two-sided 95% CI for the ratio of the hSBA GMTs at 28 days following vaccination was within this equivalence interval, the two vaccine groups would be declared equivalent with respect to the immune response to the vaccines.</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
            <method_desc>95% CIs for the GMTs ratios was obtained by exponentiating difference of least square means of log10-transformed titers and both the limits of 95% CIs</method_desc>
            <param_type>hSBA GMT ratios</param_type>
            <param_value>0.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>0.89</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number Of Subjects Reporting Solicited Local And Systemic Adverse Events</title>
        <description>Safety was assessed as the number of subjects who reported solicited local and systemic adverse events following a single injection with either MenC-CRM LIQ or MenC-CRM ROS or MenC-CRM EMV.
Safety was also assessed in subjects who mistakenly received MenC-CRM EMV instead of MenC-CRM ROS.</description>
        <time_frame>From day 1 through day 7</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Analysis was done on the safety dataset, i.e. the subjects in the exposed population who provided postvaccination safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>MenC-CRM LIQ</title>
            <description>Subjects received 1 injection of MenC-CRM vaccine, liquid formulation.</description>
          </group>
          <group group_id="O2">
            <title>MenC-CRM ROS</title>
            <description>Subjects received 1 injection of MenC-CRM vaccine, lyophilized formulation produced with drug substance manufactured at Rosia, Italy.</description>
          </group>
          <group group_id="O3">
            <title>MenC-CRM EMV</title>
            <description>Subjects received 1 injection of MenC-CRM vaccine, lyophilized formulation produced with drug substance manufactured at Emeryville, USA.</description>
          </group>
          <group group_id="O4">
            <title>MenC-CRM ROS_EMV</title>
            <description>Subjects enrolled to receive MenC-CRM ROS, but were mistakenly administered 1 injection of MenC-CRM EMV</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="299"/>
                  <measurement group_id="O2" value="267"/>
                  <measurement group_id="O3" value="304"/>
                  <measurement group_id="O4" value="119"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number Of Subjects Reporting Solicited Local And Systemic Adverse Events</title>
            <description>Safety was assessed as the number of subjects who reported solicited local and systemic adverse events following a single injection with either MenC-CRM LIQ or MenC-CRM ROS or MenC-CRM EMV.
Safety was also assessed in subjects who mistakenly received MenC-CRM EMV instead of MenC-CRM ROS.</description>
            <units>Number of subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any Local</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="124"/>
                  <measurement group_id="O2" value="115"/>
                  <measurement group_id="O3" value="148"/>
                  <measurement group_id="O4" value="58"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site Tenderness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="88"/>
                  <measurement group_id="O2" value="64"/>
                  <measurement group_id="O3" value="101"/>
                  <measurement group_id="O4" value="41"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site Erythema</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="77"/>
                  <measurement group_id="O2" value="67"/>
                  <measurement group_id="O3" value="93"/>
                  <measurement group_id="O4" value="38"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site Induration</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="47"/>
                  <measurement group_id="O2" value="40"/>
                  <measurement group_id="O3" value="68"/>
                  <measurement group_id="O4" value="31"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Systemic</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="163"/>
                  <measurement group_id="O2" value="140"/>
                  <measurement group_id="O3" value="155"/>
                  <measurement group_id="O4" value="60"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change in Eating habits</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="87"/>
                  <measurement group_id="O2" value="68"/>
                  <measurement group_id="O3" value="83"/>
                  <measurement group_id="O4" value="26"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sleepiness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="66"/>
                  <measurement group_id="O2" value="55"/>
                  <measurement group_id="O3" value="56"/>
                  <measurement group_id="O4" value="24"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Persistent Crying</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="45"/>
                  <measurement group_id="O2" value="41"/>
                  <measurement group_id="O3" value="36"/>
                  <measurement group_id="O4" value="15"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Vomiting</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="11"/>
                  <measurement group_id="O3" value="7"/>
                  <measurement group_id="O4" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Diarrhea</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="42"/>
                  <measurement group_id="O2" value="30"/>
                  <measurement group_id="O3" value="34"/>
                  <measurement group_id="O4" value="17"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Irritability</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="101"/>
                  <measurement group_id="O2" value="76"/>
                  <measurement group_id="O3" value="87"/>
                  <measurement group_id="O4" value="32"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fever (≥38°C)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="11"/>
                  <measurement group_id="O3" value="18"/>
                  <measurement group_id="O4" value="13"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited local and systemic adverse events from day 1 to 7. Serious adverse events (SAEs) and Unsolicited AEs (other than SAEs) from day 1 to day 29 (1 month after first vaccination).</time_frame>
      <desc>All Solicited AEs are classified as systematic assessment and all unsolicited AEs are classified as non-systematic assessment.</desc>
      <group_list>
        <group group_id="E1">
          <title>MenC-CRM LIQ</title>
          <description>Subjects received 1 injection of MenC-CRM vaccine, liquid formulation.</description>
        </group>
        <group group_id="E2">
          <title>MenC-CRM ROS</title>
          <description>Subjects received 1 injection of MenC-CRM vaccine, lyophilized formulation produced with drug substance manufactured at Rosia, Italy.</description>
        </group>
        <group group_id="E3">
          <title>MenC-CRM EMV</title>
          <description>Subjects received 1 injection of MenC-CRM vaccine, lyophilized formulation produced with drug substance manufactured at Emeryville, USA.</description>
        </group>
        <group group_id="E4">
          <title>MenC-CRM ROS_EMV</title>
          <description>Subjects enrolled to receive MenC-CRM ROS, but were mistakenly administered 1 injection of MenC-CRM EMV</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="267"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis Rotavirus</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="267"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="196" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="178" subjects_at_risk="267"/>
                <counts group_id="E3" subjects_affected="206" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="79" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="267"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="267"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Injection Site Erythema</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="267"/>
                <counts group_id="E3" subjects_affected="93" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Injection Site Induration</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="267"/>
                <counts group_id="E3" subjects_affected="68" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="267"/>
                <counts group_id="E3" subjects_affected="101" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="41" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="101" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="267"/>
                <counts group_id="E3" subjects_affected="87" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="119"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="267"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="267"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="267"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Eating Disorder</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="267"/>
                <counts group_id="E3" subjects_affected="83" subjects_at_risk="304"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="119"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines and Diagnostics</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
